Back to Search
Start Over
Industrialized GMP Production of CD34+ Cells (ProtheraCytes®) at Clinical Scale for Treatment of Ischemic Cardiac Diseases Is Feasible and Safe.
- Source :
-
Stem Cell Reviews & Reports . Jun2022, Vol. 18 Issue 5, p1614-1626. 13p. - Publication Year :
- 2022
-
Abstract
- Regenerative medicine now needs to pass a crucial turning point, from academic research to the market. Several sources/types of cells have been experimented with, more or less successfully. CD34+ cells have demonstrated multipotent or even pluripotent capacities, making them good candidates for regenerative medicine, particularly for treating heart diseases. Strongly encouraged by the results we achieved in a pilot study using CD34+ stem cells in patients with poor-prognosis acute myocardial infarcts (AMIs), we soon began the development of an industrialized platform making use of a closed automated device (StemXpand®) and a disposable kit (StemPack®) for the large-scale expansion of CD34+ cells with reproducible good manufacturing practice (GMP). This scalable platform can produce expanded CD34+ cells (ProtheraCytes®) of sufficient quality that, interestingly, express early markers of the cardiac and endothelial pathways and early cardiac-mesoderm markers. They also contain CD34+ pluripotent cells characterized as very small embryonic-like stem cells (VSELs), capable of differentiating under appropriate stimuli into different tissue lineages, including endothelial and cardiomyocytic ones. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15508943
- Volume :
- 18
- Issue :
- 5
- Database :
- Academic Search Index
- Journal :
- Stem Cell Reviews & Reports
- Publication Type :
- Academic Journal
- Accession number :
- 157544969
- Full Text :
- https://doi.org/10.1007/s12015-022-10373-5